duang

苹果6.34亿美元专利赔偿落定，法官驳回上诉终结Masimo诉讼案_我的网站

A |     After Akhanda 2 came to a grinding halt just a couple of days before its scheduled release (on December 5), things have turned havoc for the filmmakers. While the producers got entangled in an earlier legal arbitral, efforts were on ever since to revive the film’s release. According to reports, the producers have been holding discussions with various concerned parties.               Positive signs for Akhanda 2     It looks like the makers are clearing all the decks for Akhanda 2 release. According to reports, Madras High Court has given clearance for the film’s release after all the financial issues were cleared. The development has resulted in filmmakers now eyeing December 12 as the new release date. An official confirmation from the makers is expected to be out by Tuesday evening. Fans too are eagerly waiting for the confirmation. While Akhanda 2 is showing positive signs in terms of buzz domestically, overseas, the damage could be big as a result of the delay. Even though the Boyapati Srinu directorial isn’t getting a huge and a wide release (like earlier), still the makers exude confidence that the theatre footfalls may shoot up post release. The blockbuster combination of Balakrishna and Boyapati has a huge craze, and the trade (buyers of the film) is betting on the actor and director collaboration.          Akhanda 2 needs positive talk     With the release date almost confirmed, all Akhanda 2 needs is positive talk at the box office from the premieres and release day reports. The budget reportedly shot up because the film was made lavishly. If the film has to recover the production cost and the buyers have to break even, a super hit talk is perhaps the need of the hour for Akhanda 2. In his recent interview, Balakrishna too clarified that the film demanded the budget, and that Boyapati made the film without compromising on the quality.     Also Read: Explained: Here’s Why Court Halted The Release of Balakrishna’s Film Akhanda 2。    【环球网科技综合报道】7月22日消息，据appleinsider报道称，苹果公司要求推翻6.34亿美元专利侵权赔偿及重审的请求被正式驳回。这一裁决标志着这场始于2020年、历时六年的苹果与医疗技术公司Masimo之间的专利纠纷在联邦法院层面迎来阶段性终结。         此次诉讼的核心争议在于Apple Watch的血氧监测技术。此前，陪审团裁定Apple Watch的心率监测与通知功能侵犯了Masimo的脉搏血氧测定专利，并判令苹果支付6.34亿美元赔偿金。         苹果方面曾以“Apple Watch并非涉案专利所定义的‘病人监护仪’”为由提起上诉，但法官塞尔纳在裁决中支持了陪审团的结论。随着重审请求被拒，该笔巨额赔偿基本落槌。

B |          尽管苹果在赔偿环节败诉，但在产品禁售方面，Masimo未能实现其最终诉求。

C |          值得注意的是，这笔巨额赔偿的最终接收方已发生变更。

D | 2026年6月，全球医疗科技巨头丹纳赫（Danaher）宣布以99亿美元完成对Masimo的收购。丹纳赫预计Masimo在2027年的EBITDA将超过5.3亿美元，因此苹果支付的6.34亿美元赔偿金将成为新东家的一笔可观收益。

E | （青云）。

Current article:http://www.liangkuataosanxuanmiancen.sbs/list_7nvxju/0m86.xls

Published on:15:48:19